The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Advancements in clinical trials for high-risk newly diagnosed multiple myeloma
Lisa Leypoldt, MD, University Medical Center Hamburg, Hamburg, Germany, discusses advancements in clinical trials investigating treatment approaches for high-risk newly diagnosed myeloma. The GMMG-CONCEPT (NCT03104842) and OPTIMUM/MUK Nine b (NCT03188172) showed high response rates to combination treatment in this patient population. Dr Leypoldt also mentions the CARTITUDE-5 (NCT04923893) and CARTITUDE-6 (NCT05257083) trials which are investigating ciltacabtagene autoleucel (cilta-cel) in the first-line setting, although these are not dedicated high-risk trials. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
